MRKR Nasdaq

Marker Therapeutics, Inc.

MRKR | $4.43 5.73% 5.42% 12K

(0.0% 1d) (-13.4% 1m) (355.4% 1y) (0.0% 2d) (0.0% 3d) (-2.8% 7d) (-3.96% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 39,439,834
http://www.markertherapeutics.com
Sec Filling | Patents | 28 employees

(US) Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

vaccine immunotherapy t-cell treatment ceiling

add to watch list Paper trade email alert is off

Press-releases

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
MRKR | $4.43 5.73% 5.42% 12K

Consumer Services

| -14.31% | O: -5.73% H: 5.86% C: 2.17%
hope city global medical therapeutics study

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Published: 2024-03-25 (Crawled : 22:00) - globenewswire.com
MRKR | $4.43 5.73% 5.42% 12K

Consumer Services

| -13.43% | O: -0.83% H: 2.29% C: -10.0%
therapeutics financial results

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Published: 2024-03-22 (Crawled : 17:00) - globenewswire.com
MRKR | $4.43 5.73% 5.42% 12K

Consumer Services

| -9.7% | O: 2.06% H: 3.68% C: 3.68%
conference cell therapeutics therapy

Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
Published: 2024-03-12 (Crawled : 17:00) - biospace.com/
PLRX | $12.505 -0.75% -0.76% 240K

Health Technology

| -13.28% | O: 0.0% H: 6.88% C: 4.2%
MRKR | $4.43 5.73% 5.42% 12K

Consumer Services

| 1.21% | O: -1.2% H: 4.88% C: 3.17%
therapeutics

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
Published: 2024-01-22 (Crawled : 12:30) - globenewswire.com
MRKR | $4.43 5.73% 5.42% 12K

Consumer Services

| -3.01% | O: 1.62% H: 8.66% C: 3.87%
mt-601 approval international therapeutics

Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates DelveInsight
Published: 2024-01-08 (Crawled : 22:00) - prnewswire.com
INAB | $1.035 3.51% 3.39% 280K

| -33.33% | O: 2.67% H: 13.64% C: 9.74%
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -7.52% | O: 0.23% H: 0.0% C: 0.0%
MCRB | $0.7629 22.14% 18.13% 12M

Health Technology

| -60.26% | O: 26.92% H: 3.54% C: -27.78%
DTIL | $10.33 6.72% 6.29% 31K

Health Technology

| 2332.16% | O: 10.0% H: 14.23% C: 0.09%
OMER | $3.08 0.0% 210K

Health Technology

| -13.73% | O: -0.56% H: 13.38% C: 11.27%
MRKR | $4.43 5.73% 5.42% 12K

Consumer Services

| -15.18% | O: 1.21% H: 0.0% C: -0.8%
INCY | $51.62 -0.58% -0.58% 2.5M

Health Technology

| -21.12% | O: 0.0% H: 0.53% C: -2.19%
cell study market

NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO
Published: 2024-01-08 (Crawled : 13:30) - globenewswire.com
NHWK | $0.4135 0.0% 170K

Manufacturing

| -9.77% | O: -4.55% H: 11.83% C: 2.19%
MRKR | $4.43 5.73% 5.42% 12K

Consumer Services

| -13.07% | O: -1.87% H: 7.82% C: 4.44%
BLCM | $0.0748 381.28% 6.1K

Health Technology

| -50.13% | O: -7.0% H: 0.36% C: -5.38%
change

NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings
Published: 2024-01-08 (Crawled : 18:00) - biospace.com/
MRKR | $4.43 5.73% 5.42% 12K

Consumer Services